P PUMA BIOTECHNOLOGY INC
| Market Cap | $351.05M |
| P/E Ratio | 11.31 |
| Forward P/E | 10.62 |
| Dividend Yield | — |
| Beta | 1.18 |
| 52W Range | $2.74 - $7.68 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Sarah Ketterer Causeway Capital Management | 0.00% | $79.00K | 13,310 | Reduce 5.57% |
Insider Trading
| Insider Name of the company insider who made the trade 7 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| HUNT DOUGLAS MSee Remarks | Sale | 5,014 | $5.88 | $29.48K | 07 Jan 2026 | 08 Jan 2026 |
| NOUGUES MAXIMO FChief Financial Officer | Sale | 6,405 | $5.88 | $37.65K | 07 Jan 2026 | 08 Jan 2026 |
| AUERBACH ALAN HPresident and CEO | Sale | 18,012 | $5.88 | $105.89K | 07 Jan 2026 | 08 Jan 2026 |
| HUNT DOUGLAS MSee Remarks | Sale | 3,973 | $5.84 | $23.22K | 06 Jan 2026 | 08 Jan 2026 |
| AUERBACH ALAN HPresident and CEO | Sale | 16,938 | $5.84 | $98.99K | 06 Jan 2026 | 08 Jan 2026 |
| NOUGUES MAXIMO FChief Financial Officer | Sale | 4,540 | $5.84 | $26.53K | 06 Jan 2026 | 08 Jan 2026 |
| MILLER MICHAEL PATRICK | Sale | 20,000 | $4.86 | $97.23K | 11 Nov 2025 | 13 Nov 2025 |
Frequently Asked Questions
What is PBYI stock price today?
PUMA BIOTECHNOLOGY INC (PBYI) is currently trading at $6.90. The stock has a 52-week range of $2.74 to $7.68 and a market capitalization of $351.05M.
Is PBYI a good stock to buy in 2026?
PUMA BIOTECHNOLOGY INC has a P/E ratio of 11.3 (forward P/E: 10.6), a dividend yield of none, and 1-year performance of +136.3%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling PBYI stock?
There have been 7 insider transactions for PBYI in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has PBYI stock performed over the past year?
PUMA BIOTECHNOLOGY INC (PBYI) has returned +136.3% over the past 12 months. The stock traded between $2.74 and $7.68 during this period, and is currently at $6.90.
Which hedge funds own PBYI (PUMA BIOTECHNOLOGY INC)?
1 tracked hedge funds currently hold PBYI in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is PBYI's market cap and valuation?
PUMA BIOTECHNOLOGY INC (PBYI) has a market capitalization of $351.05M. The trailing P/E ratio is 11.3 and forward P/E is 10.6. The stock is classified in the Healthcare sector.
What is PBYI's revenue and profitability?
PUMA BIOTECHNOLOGY INC reported revenue of $228.37M with net income of $31.11M and a profit margin of 0.14%. The stock has a beta of 1.18.
What sector is PBYI in and who are its biggest institutional holders?
PUMA BIOTECHNOLOGY INC (PBYI) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.